12,083 Shares in Kymera Therapeutics, Inc. $KYMR Bought by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG purchased 12,083 Kymera Therapeutics shares worth approximately $1.386 million during the second quarter. Several other institutional investors also increased their holdings.
• Kymera reported stronger-than-expected quarterly results, with a loss of $0.62 per share versus the $0.71 estimate and revenue of $65 million, up 465.2% year over year.
• Analysts maintain a Moderate Buy consensus, with 20 Buy, two Hold and one Sell rating and an average price target of $125.65. However, insiders sold roughly $387.6 million of stock over the past 90 days.

B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,083 shares of the company's stock, valued at approximately $1,386,000.

Several other large investors have also added to or reduced their stakes in the business. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after acquiring an additional 98 shares during the period. Smartleaf Asset Management LLC raised its holdings in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC raised its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after buying an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $63,000. Finally, Osaic Holdings Inc. lifted its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after buying an additional 1,083 shares in the last quarter.

Get Kymera Therapeutics SMS alerts:

Sign Up

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $119.80 on Monday. The company has a market cap of $9.96 billion, a PE ratio of -36.98 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52 week low of $39.84 and a 52 week high of $130.05. The firm's 50-day simple moving average is $109.42 and its two-hundred day simple moving average is $92.15.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter in the previous year, the firm earned ($0.95) EPS. The company's quarterly revenue was up 465.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Guggenheim boosted their price objective on Kymera Therapeutics from $125.00 to $135.00 and gave the stock a "buy" rating in a report on Tuesday, July 28th. Barclays raised their target price on Kymera Therapeutics from $133.00 to $139.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Royal Bank Of Canada lowered Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and increased their price target for the company from $106.00 to $115.00 in a research report on Monday, July 13th. B. Riley Financial raised their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Finally, Bank of America lifted their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Twenty research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $125.65.

Insiders Place Their Bets

In related news, Director Bvf Partners L. P/Il sold 1,578,800 shares of Kymera Therapeutics stock in a transaction on Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Booth sold 31,283 shares of the business's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the completion of the sale, the director directly owned 461,794 shares of the company's stock, valued at $50,557,207.12. This represents a 6.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,604,813 shares of company stock valued at $387,557,004 over the last 90 days. Company insiders own 15.98% of the company's stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source